Global Childhood Cancer Access

By Crystal Lubbe

February 27, 2025

Global Childhood Cancer Access

What if no child had to face cancer without access to treatment? The World Health Organization (WHO) has launched the Global Childhood Cancer Access initiative in collaboration with St. Jude Children’s Research Hospital. This innovative program aims to provide critically needed childhood cancer medicines to low- and middle-income countries (LMICs).

Scope and Impact

The platform has begun distributing medicines in two of the six pilot countries: Mongolia and Uzbekistan. Future shipments are planned for Ecuador, Jordan, Nepal, and Zambia. This initiative aims to reach approximately 5,000 children with cancer across at least 30 hospitals in these countries within 2025. The long-term goal is to expand to 50 countries in the next 5 to 7 years, providing access to medicines for about 120,000 children with cancer in LMICs.

Global Disparities

Childhood cancer survival rates in LMICs are significantly lower than those in high-income countries, often below 30%. This disparity arises from factors such as lack of appropriate treatment and treatment disruptions. It is estimated that 70% of children with cancer in these settings die from the disease.

Collaborative Model

The platform unites governments, the pharmaceutical industry, and NGOs in a unique collaboration, consolidating demand and shaping the market. Furthermore, it supports countries in medicine selection and develops treatment standards. Key partners, such as UNICEF Supply Division and PAHO Strategic Fund, strengthen the initiative. Moreover, it focuses on capacity building and long-term sustainability. By providing local support, data sharing, and policy development, the program helps countries maintain independent access to essential medicines.

Quotes and Statements

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasised the importance of providing quality-assured cancer medicines to pediatric hospitals in LMICs, highlighting the partnership’s goal of bringing health and hope to children worldwide. James R. Downing, MD, President and CEO of St. Jude, stated that the initiative aligns with St. Jude’s founding dream: no child should die from cancer at the dawn of life, regardless of their location.

Broader Impact

The Global Childhood Cancer Access platform is part of the St. Jude Strategic Plan to accelerate progress on catastrophic childhood diseases globally. It synergises with the Global Initiative for Childhood Cancer, which supports more than 70 governments in building local cancer programs, aiming to boost survival rates to 60% by 2030.

This initiative represents a significant step toward addressing the stark disparities in childhood cancer treatment and survival rates globally, particularly in resource-limited settings. The Global Childhood Cancer Access initiative is set to reshape the future of childhood cancer care around the world.

Reference url

Recent Posts

Innovative Therapies Access Portugal
Evaluating Innovative Therapies Access in Portugal

By João L. Carapinha

June 11, 2026

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...
Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...
clinical skill assessment
Transforming Clinical Skill Assessment with Intelligent Evaluation Systems

By HEOR Staff Writer

June 10, 2026

Clinical skill assessment has long been hampered by subjective judgments and variability among examiners. A novel unified intelligent framework replaces these manual observations with contrastive learning to deliver objective, trace...